Aponia 500 Tablet: Each film coated tablet contains Nabumetone USP 500 mg.
Aponia 750 Tablet: Each film coated tablet contains Nabumetone USP 750 mg.
Aponia 1000 Tablet: Each film coated tablet contains Nabumetone USP 1000 mg.
Nabumetone is a naphthylalkanone. It is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and COX-2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis. The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors.
For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
a) Route of administration: Oral:
a) With medicine: Caution should be exercised when administering Nabumetone with Warfarin. Because of its affinity for protein, active metabolite 6-MNA may displace other protein-bound drugs from their binding site..
b) With food & others: interacted with heavily salted foods.:
Overdose:
Symptoms following acute NSAIDs overdoses are usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression, anaphylactic reactions may occur. Patients should be managed by symptomatic and supportive care following a NSAIDs overdose. Emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose (5 to 10 times the usual dose).
Pregnancy: Pregnancy Category C. There are no adequate, well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Use of Nabumetone during the third trimester of pregnancy is not recommended.
It is not known if Nabumetone is safe and effective in children.
Nabumetone cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. The pharmacological activity of Nabumetone in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
Store below 30°C. Protect from light and moisture. Keep all medicines out of reach of children.